Incyte (INCY) Liabilities and Shareholders Equity (2010 - 2026)

Incyte's (INCY) quarterly Liabilities and Shareholders Equity came in at $7.9 billion in Q2 2026, up 35.24% YoY from $5.8 billion in Q2 2025, and up 7.27% on a QoQ basis from $7.3 billion in Q1 2026.

Incyte (INCY) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends

Incyte (INCY) has 17 years of Liabilities and Shareholders Equity data on file, last reported at $7.9 billion in Q2 2026.

  • Quarterly Liabilities and Shareholders Equity rose 35.24% year-over-year to $7.9 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $28.5 billion (up 29.38% YoY) and the FY2025 annual result came in at $7.0 billion, up 27.8% from the prior year.
  • Liabilities and Shareholders Equity grew to $7.9 billion in Q2 2026, from $7.3 billion in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $7.9 billion in Q2 2026 to a low of $4.7 billion in Q2 2024.
  • A 5-year average of $6.1 billion and a median of $5.8 billion in 2022 frame the typical range for Liabilities and Shareholders Equity.
  • Annual changes were most pronounced in 2022 — Liabilities and Shareholders Equity jumped 38.04% — and 2024, when it retreated 24.91%.
  • Tracing INCY's Liabilities and Shareholders Equity over 5 years: stood at $5.8 billion in 2022, then advanced by 16.11% to $6.8 billion in 2023, then declined by 19.73% to $5.4 billion in 2024, then gained by 27.8% to $7.0 billion in 2025, then gained by 13.15% to $7.9 billion in 2026.
  • The last three Liabilities and Shareholders Equity figures came in at $7.9 billion (Q2 2026), $7.3 billion (Q1 2026), and $7.0 billion (Q4 2025), per Business Quant data.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Liabilities and Shareholders Equity (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 27.42 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 41.73 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 10.03 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.32 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 9.18 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 15.59 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 19.82 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 5.56 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 2.10 Bn
10 Incyte 24.15 Bn 19.61 Bn 1.57 Bn 7.87 Bn

Historic Data

Download Data
DateValue
Jun 30, 2026 7.87 Bn
Mar 31, 2026 7.34 Bn
Dec 31, 2025 6.96 Bn
Sep 30, 2025 6.33 Bn
Jun 30, 2025 5.82 Bn
Mar 31, 2025 5.75 Bn
Dec 31, 2024 5.44 Bn
Sep 30, 2024 5.01 Bn
Jun 30, 2024 4.66 Bn
Mar 31, 2024 7.14 Bn
Dec 31, 2023 6.78 Bn
Sep 30, 2023 6.39 Bn
Jun 30, 2023 6.21 Bn
Mar 31, 2023 5.80 Bn
Dec 31, 2022 5.84 Bn
Sep 30, 2022 5.51 Bn
Jun 30, 2022 5.32 Bn
Mar 31, 2022 5.05 Bn
Dec 31, 2021 4.93 Bn
Sep 30, 2021 4.20 Bn